Patents Issued in April 13, 2017
-
Publication number: 20170101616Abstract: A method and system for hydrogen production from organic material such as waste. The system includes a bioreactor for continuous anerobic fermentation to produce hydrogen in which a mixture containing a microorganism and organic material is sonicated. The system optionally includes a biomethanator connected in-line with the bioreactor.Type: ApplicationFiled: February 26, 2016Publication date: April 13, 2017Inventors: Elsayed Elrefaey ELBESHBISHY, George F. NAKHLA
-
Publication number: 20170101617Abstract: An imaging section of a microscope apparatus captures a plurality of microscope images each having the focal position which differs in the field being same with a light flux having passed through a microscopic optical system. A region separating section separates a cellular region from a non-cellular region by using the plurality of the microscope images. A focusing position calculating section finds a focusing position in a target pixel included in the cellular region based on a brightness change in the position being same in the plurality of the microscope images. A three dimensional information generating section generates three dimensional information of a cultured cell based on a position of the cellular region and the focusing position in the target pixel.Type: ApplicationFiled: December 23, 2016Publication date: April 13, 2017Applicant: NIKON CORPORATIONInventor: Yasujiro KIYOTA
-
Publication number: 20170101618Abstract: A fluid pumping and bioreactor system including at least two cassettes, at least one storage reservoir, at least one bioreactor, at least one manifold including valve modules, and tubing to connect the cassettes to the storage reservoir and the bioreactor. The cassettes can include pumps, valves, and fluid conduits and can be communicatively connected to the at least one manifold. The bioreactor can include an adapter and fluid conduits extending through the adapter from the exterior of the bioreactor to the interior of the bioreactor. System and method for generating a tissue for transplant by decellularizing and recellularizing a supplied tissue.Type: ApplicationFiled: October 7, 2016Publication date: April 13, 2017Inventors: Dean Kamen, Jason A. Demers, Frederick Morgan, Timothy D. Moreau, Brian D. Tracey, Matthew Ware, Dirk A. van der Merwe, Richard J. Lanigan, Michael A. Baker, David Blumberg, JR.
-
Publication number: 20170101619Abstract: The invention relates to a photobioreactor for cultivating photosynthetic micro-organisms, comprising: a) at least one cultivation container (1) for containing the culture medium (3) of the micro-organisms, b) photovoltaic cells (2) isolated from the culture medium (3), emitting light towards the culture medium (3), and c) means (4) for powering the photovoltaic cells (2) in order to operate the photovoltaic cells in light emission mode.Type: ApplicationFiled: December 20, 2016Publication date: April 13, 2017Inventors: Jacques Bourgoin, Michel Conin, Alain Friederich, Guocai Sun
-
Publication number: 20170101620Abstract: The example of the present invention discloses a klebsiella sp. strain and a method for preparing a microbial flocculant from the same. This strain is a Klebsiella sp. strain LDX1-1 which has been preserved in the China General Microbiological Culture Collection Center on Sep. 7, 2015, and the preservation number is CGMCC No. 11330. This strain can be used for preparing a microbial flocculate in an activated fermentation way.Type: ApplicationFiled: June 16, 2016Publication date: April 13, 2017Inventor: XINGSHE LUAN
-
Publication number: 20170101621Abstract: The invention relates to a zinc-enriched biomass comprising living or subsequently killed micro-organisms, selected from the group consisting of Streptococcus thermophilus and Bifidobacterium animalis subsp. lactis and combinations thereof, a method for the manufacture of said zinc-enriched biomass, as well as food preparations, nutraceutic products, functional foods, cosmetic and cosmeceutic products, and food supplements, comprising the said biomass. Furthermore, new micro-organism strains are described which are able to concentrate zinc within the cell in very high amounts and therefore are particularly suitable for use in the method of the invention.Type: ApplicationFiled: October 27, 2016Publication date: April 13, 2017Inventors: Alberto BENEDETTI, Francesco GIRARDO
-
Publication number: 20170101622Abstract: A method of obtaining a neural multipotent, unipotent or somatic cell, comprising: i) providing a cell of a first type which is not a neural multipotent, unipotent or somatic cell; ii) introducing into the cell of a first type an agent capable of remodeling the chromatin and/or DNA of the cell, wherein the agent capable of remodeling the chromatin and/or DNA is a histone acetylator, an inhibitor of histone deacetylation, a DNA demethylator, and/or a chemical inhibitor of DNA methylation; iii) increasing directly or indirectly the endogenous expression of at least one neural multipotent or unipotent gene regulator in the cell of a first type, to a level at which the gene regulator is capable of driving transformation of the cell of a first type into the neural multipotent, unipotent or somatic cell, wherein the gene regulator is Msi1, Ngn2, Sox2, Ascl1, Zic1 or a combination thereof; and iv) placing or maintaining the cell in a neural cell culture medium and maintaining intracellular levels of the reprogramminType: ApplicationFiled: October 19, 2016Publication date: April 13, 2017Inventors: Jan-Eric Ahlfors, Rouwayda El-Ayoubi
-
Publication number: 20170101623Abstract: An in vitro human neural multipotent, unipotent, or somatic cell possessing all of the following characteristics: is derived from the reprogramming of a somatic cell, a progenitor cell or a stem cell that exhibits at least a transient increase in intracellular levels of at least one reprogramming agent; is not differentiated from a pluripotent cell; expresses one or more markers of a multipotent, unipotent or somatic cell not characteristic of a neural stem cell, neural precursor cell, neural progenitor cell, neuroblast, or neuron; is not a cancerous cell; is stable and not artificially maintained by forced gene expression and may be maintained in standard neural stem cell media or neural media; and does not exhibit uncontrolled growth, teratoma formation, and tumor formation in vivo; wherein the cell comprises at least one polypeptide or an expression vector encoding at least one polypeptide selected from the group consisting of: Musashi1 (Msi1); Ngn2; Msi1 and Ngn2; Msi1 and methyl-CpG binding domain proteiType: ApplicationFiled: October 19, 2016Publication date: April 13, 2017Inventors: Jan-Eric Ahlfors, Rouwayda El-Ayoubi
-
Publication number: 20170101624Abstract: The present disclosure encompasses methods of enhancing T cell longevity and/or T cell function by promoting mitochondrial fusion and/or mitochondrial structural remodeling including cristae. Compositions comprising the enhanced T cells may be used in adoptive cellular immunotherapy.Type: ApplicationFiled: October 6, 2016Publication date: April 13, 2017Inventors: Erika L. Pearce, Michael D. Buck, David O'Sullivan
-
Publication number: 20170101625Abstract: The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting.Type: ApplicationFiled: October 28, 2016Publication date: April 13, 2017Inventor: ALFRED E. SLANETZ
-
Publication number: 20170101626Abstract: A method of obtaining a cardiac multipotent or unipotent cell, comprising: i) providing a cell of a first type which is not a cardiac multipotent or unipotent cell; ii) introducing into the cell of a first type an agent capable of remodeling the chromatin and/or DNA of the cell, wherein the agent capable of remodeling the chromatin and/or DNA is a histone acetylator, an inhibitor of histone deacetylation, a DNA demethylator, and/or a chemical inhibitor of DNA methylation; iii) introducing into the cell of a first type a reprogramming polypeptide and/or a polynucleotide encoding said reprogramming polypeptide, wherein the reprogramming polypeptide comprises Mesp1, Brachyury (T), Nkx2.5, and/or Tbx5; and iv) placing or maintaining the cell in a cardiac cell culture medium and maintaining intracellular levels of the reprogramming polypeptide or the polynucleotide encoding the reprogramming polypeptide for a sufficient period of time to allow a cardiac multipotent or unipotent cell to be obtained.Type: ApplicationFiled: October 19, 2016Publication date: April 13, 2017Inventors: Jan-Eric Ahlfors, Rouwayda El-Ayoubi
-
Publication number: 20170101627Abstract: Provided herein are cells and methods for reprogramming iPS cells from a supercentanarian and their differentiated derivatives having differences from non-supercentenarian iPS derived cells that contribute to disease resistance and longevity. Additionally, provided herein are methods for treatment and prevention of age related diseases by administration of therapeutic sciPS derived cells or cell derived reagents. Also provided herein, are methods for identifying reagents for treatment of age related diseases using sciPS cell-based assays.Type: ApplicationFiled: October 21, 2016Publication date: April 13, 2017Inventor: David J. Larocca
-
Publication number: 20170101628Abstract: The embodiments of the invention described herein relate to systems and methods for culturing and/or maintaining intestinal cells, tissues and/or organoids in vitro. The cells, tissues and/or organoids cultured according to the methods and systems described herein can mimic or reproduce natural intestinal epithelial structures and behavior as well as support co-culture of intestinal microflora.Type: ApplicationFiled: December 22, 2016Publication date: April 13, 2017Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Donald E. INGBER, Hyun Jung KIM
-
Publication number: 20170101629Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.Type: ApplicationFiled: October 6, 2016Publication date: April 13, 2017Inventors: Jeremy Minshull, Mark Welch, Sridhar Govindrajan, Maggie Lee, Kate Caves, Jon Ness
-
Publication number: 20170101630Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.Type: ApplicationFiled: October 6, 2016Publication date: April 13, 2017Inventors: Jeremy Minshull, Mark Welch, Sridhar Govindrajan, Maggie Lee, Kate Caves, Jon Ness
-
Publication number: 20170101631Abstract: The invention relates to a genetically engineered bacterium comprising an energy-generating fermentation pathway and methods related thereto. In particular, the invention provides a bacterium comprising a phosphate butyryltransferase (Ptb) and a butyrate kinase (Buk) (Ptb-Buk) that act on non-native substrates to produce a wide variety of products and intermediates. In certain embodiments, the invention relates to the introduction of Ptb-Buk into a C1-fixing microoorgansim capable of producing products from a gaseous substrate.Type: ApplicationFiled: October 13, 2016Publication date: April 13, 2017Inventors: Michael Koepke, Rasmus Overgaard Jensen, James Bruce Yarnton Haycock Behrendorff, Ryan Edward Hill
-
Publication number: 20170101632Abstract: Disclosed are DNA polymerases having increased reverse transcriptase efficiency relative to a corresponding, unmodified polymerase. The polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the DNA polymerases.Type: ApplicationFiled: October 21, 2016Publication date: April 13, 2017Inventor: Shawn Suko
-
Publication number: 20170101633Abstract: A method of maintaining disease stability in a subject having Gaucher's disease following switch from enzyme replacement therapy (ERT) is provided. The method comprising orally administering to the subject a therapeutically effective amount of recombinant glucocerebrosidase (GCD) comprised in plant cells, thereby maintaining disease stability following switch.Type: ApplicationFiled: February 9, 2015Publication date: April 13, 2017Inventors: Yoseph SHAALTIEL, Einat ALMON
-
Publication number: 20170101634Abstract: A process for preparing Streptomyces koganeiensis ATCC 31394 hyaluronidase includes obtaining hyaluronidase having molecular weight of 21.6 kDalton, which has hyaluronidase activity and stability markedly higher than those of the hyaluronidase obtained from such microorganism to date.Type: ApplicationFiled: August 2, 2016Publication date: April 13, 2017Applicant: FIDIA FARMACEUTICI S.P.A.Inventors: Luciano MESSINA, Susanna VACCARO, Salvatore CARUSO, Giovanni GENNARI
-
Publication number: 20170101635Abstract: The present invention relates to GH Family 11 xylanase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: May 22, 2015Publication date: April 13, 2017Applicant: NOVOZYMES A/SInventors: James Lavigne, Brian R. Scott, Daniel Sebastian Kolczynski
-
Publication number: 20170101636Abstract: The present invention provides protease-cleavage resistant molecules comprising Shiga toxin effector polypeptides capable of exhibiting potent, Shiga toxin functions (e.g. subcellular routing and cytotoxicity). The present invention also provides protease-cleavage resistant, cell-targeting molecules for targeting specific cell types, e.g., infected or malignant cells. Certain molecules of the present invention are cytotoxic, and certain cell-targeting molecules of the present invention may be used for the targeted killing of specific cell types and the treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections. Certain cell-targeting molecules of the invention exhibit improved, in vivo tolerability as compared to related cell-targeted molecules comprising protease-cleavage sensitive, wild-type, Shiga toxin effector polypeptides.Type: ApplicationFiled: June 10, 2015Publication date: April 13, 2017Applicant: Molecular Templates, Inc.Inventors: Eric Poma, Erin Willert, Jack Higgins, Jason Kim
-
Publication number: 20170101637Abstract: The present invention provides a novel psicose epimerase derived from Flavonifractor plautii and capable of converting fructose to psicose. The novel psicose epimerase according to the present invention possesses an activity producing psicose by epimerizing the carbon-3 position of fructose, and has maximal activity for the conversion of fructose to psicose at a relatively high temperature and a pH less than or equal to neutral, has excellent thermal stability, and can mass-produce psicose from fructose in a high yield for a short amount of time. Therefore, the psicose epimerase according to the present invention is advantageous in the industrial production of psicose, and it is expected that the psicose produced thereby can be usefully utilized in the functional sugar industry and also as materials for health food, medicine, cosmetics, and the like using the psicose.Type: ApplicationFiled: May 22, 2015Publication date: April 13, 2017Inventors: Tae Gyun KIM, Min Su KIM, Tae Yong KIM, Eun Bum SONG, Deok Kun OH
-
Publication number: 20170101638Abstract: The present invention provides various combinations of genetic modifications to a. transformed host cell that provide increase conversion of carbon to a chemical product. The present invention also provides methods of fermentation and methods of making various chemical products.Type: ApplicationFiled: September 19, 2016Publication date: April 13, 2017Inventors: Hans Liao, Christopher Patrick Mercogliano, Travis Robert Wolter, Michael Tai Man Louie, Wendy Kathleen Ribble, Tanya E. W. Lipscomb, Eileen Colie Spindler, Michael D. Lynch
-
Publication number: 20170101639Abstract: The present invention provides a composition for suppressing the expression of the CKAP5 gene, the composition comprising a lipid particle containing a double-stranded nucleic acid as a drug and a cationic lipid, the double-stranded nucleic acid having an antisense strand having a base sequence complementary to the sequence of at least 19 continuous bases in CKAP5 gene mRNA of any one of SEQ ID NOs: 1 to 6, the cationic lipid being represented by formula (I): wherein R1 and R2 are the same or different and are each linear or branched alkyl, alkenyl or alkynyl of 12 to 24 carbon atoms; L1 and L2 are the same or different and are each —CO—O— or —O—CO—; a and b are the same or different and are each 1 to 3; and R3 is a hydrogen atom, alkyl of 1 to 6 carbon atoms, or alkenyl of 3 to 6 carbon atoms; a medicament comprising the composition, and the like.Type: ApplicationFiled: June 4, 2015Publication date: April 13, 2017Applicants: Kyowa Hakko Kirin Co., Ltd., DICERNA PHARMACEUTICALS, INC.Inventors: Hayato YABUUCHI, Kana KURIHARA, Ayumi YAMADA, Keiko NAKAHASHI, Kentaro HATANAKA, Shiho TOMURA
-
Publication number: 20170101640Abstract: The present invention relates to miR145, miR132, miR212, and the genes or gene products regulated by these miRNAs. miR145 is downregulated in cells infected with HCMV. This downregulation modulates expression of miR145 target genes, including IRS-1. Transfection of cells with a miR145 agent, such as a miR145 mimetic, reduces HCMV replication and protein expression. miR132 and miR212 are upregulated in cells infected with HCMV. This upregulation modulates expression of miR132 and miR212 target genes, including MeCP2 and RICS. Transfection of cells with a miR132 and/or a miR212 antagonist reduces HCMV replication and protein expression. Accordingly, the invention provides methods of attenuating HCMV replication by modulating, for example, miR145, miR132, and/or miR212, and targets thereof. Also provided are methods of detecting an HCMV infection, and compositions and kits useful for attenuating HCMV replication.Type: ApplicationFiled: December 19, 2016Publication date: April 13, 2017Inventors: Timothy F. Kowalik, Mariluz Rodriguez-Gonzalez, Alexander Lagadinos
-
Publication number: 20170101641Abstract: Disclosed herein include compositions and methods of modulating protein expression that utilizes an activator or a repressor of a non-sense mediated RNA decay switch exon (NSE). In some embodiments, also included herein are compositions and methods of modulating protein expression that uses an agent that targets a transposed element.Type: ApplicationFiled: October 7, 2016Publication date: April 13, 2017Inventors: Igor Vorechovsky, Jana Kralovicova
-
Publication number: 20170101642Abstract: The present invention is directed to compositions targeting the signal peptidase complex and methods of use in treating and preventing flavivirus infection.Type: ApplicationFiled: October 10, 2016Publication date: April 13, 2017Inventors: Michael Diamond, Rong Zhang
-
Publication number: 20170101643Abstract: The present invention provides fungal proteases and improved fungal strains that are deficient in protease production.Type: ApplicationFiled: December 20, 2016Publication date: April 13, 2017Inventors: Lorand Szabo, Zsolt Molnar, Attila Laszlo Nemeth
-
Publication number: 20170101644Abstract: The present invention lies in the field of molecules known as “small interfering RNA” with therapeutic applications. siRNAs have the ability to reduce gene expression in an extremely specific way (1). These are small sequences of double-strand RNA, normally used in laboratory to modify cell function, which revolutionized cell biology by allowing previously precluded molecular manipulations.Type: ApplicationFiled: May 21, 2015Publication date: April 13, 2017Applicant: Universita degli Studi dell"AquillaInventors: Anna Maria TETI, Nadia RUCCI, Mattia CAPULLI, Antonio MAURIZI
-
Publication number: 20170101645Abstract: Aspects of the disclosure relate to methods of altering RNA splicing in a subject. In some embodiments, methods are provided for correcting splicing in a cell that contains a DYSF gene having a mutation that results in defective splicing.Type: ApplicationFiled: June 3, 2015Publication date: April 13, 2017Applicant: University of MassachusettsInventors: Robert H. Brown, JR., Janice A. Dominov
-
Publication number: 20170101646Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.Type: ApplicationFiled: October 6, 2016Publication date: April 13, 2017Inventors: Jeremy Minshull, Mark Welch, Sridhar Govindrajan, Maggie Lee, Kate Caves, Jon Ness
-
Publication number: 20170101647Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.Type: ApplicationFiled: October 6, 2016Publication date: April 13, 2017Inventors: Jeremy Minshull, Mark Welch, Sridhar Govindrajan, Maggie Lee, Kate Caves, Jon Ness
-
Publication number: 20170101648Abstract: The technology relates in part to biological methods for producing a fatty dicarboxylic acid and engineered microorganisms capable of such production.Type: ApplicationFiled: September 21, 2016Publication date: April 13, 2017Inventors: Tom BEARDSLEE, Stephen Picataggio, Alex Hutagalung, Tom Fahland
-
Publication number: 20170101649Abstract: Embodiments of the present invention comprise altering the biosynthesis and accumulation of sucrose in legumes by transforming the plants with the sucrose phosphate synthase (SPS) gene of maize, and closely related regulatory genes. Embodiments of the present invention further comprise altering the assimilation of nitrogen in legumes by transforming the plants with the glutamine synthetase (GS) gene of soybean, and closely related regulatory genes. Embodiments of the present invention further comprise transforming legume plants with both SPS and GS genes. In addition, embodiments of the present invention relate to enhancing expression of transgenes through the 5? UTR of the glycine max (soybean) cytosolic glutamine synthetase (Gmgln?1) gene.Type: ApplicationFiled: August 9, 2016Publication date: April 13, 2017Inventors: Champa Sengupta Gopalan, Jose L. Ortega-Carranza
-
Publication number: 20170101650Abstract: The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties compared to a reference plant. Sequence information related to these polynucleotides and polypeptides can also be used in bioinformatic search methods and is also disclosed.Type: ApplicationFiled: October 21, 2016Publication date: April 13, 2017Inventors: Jose Luis Riechmann, Robert Creelman, Oliver Ratcliffe, T. Lynne Reuber, Neal I. Gutterson
-
Publication number: 20170101651Abstract: This disclosure concerns nucleic acid molecules and methods of use thereof for control of coleopteran and hemipteran pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in coleopteran and hemipteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of coleopteran and hemipteran pests, and the plant cells and plants obtained thereby.Type: ApplicationFiled: October 4, 2016Publication date: April 13, 2017Applicant: Dow AgroSciences LLCInventors: Kenneth E. Narva, Elane Fishilevich, Murugesan Rangasamy, Meghan L. Frey, Wendy Lo, Sarah E. Worden, Premchand Gandra
-
Publication number: 20170101652Abstract: There are disclosed hybrid proteins comprising at least one signal sequence; at least one DNA binding domain; and at least one cell penetrating peptide (CPP) domain. In embodiments the CPP domain is a TAT domain, and the DNA binding domain is a HU domain. There is also disclosed the use of the hybrid proteins to introduce exogenous DNA into target cells, and methods for introducing exogenous DNA into target cells using the hybrid proteins.Type: ApplicationFiled: October 20, 2016Publication date: April 13, 2017Inventors: HERBERT ALEXANDER GRAVES, Mark Andrew Fox
-
Publication number: 20170101653Abstract: The present invention is related to a recombinant host cell, in particular a yeast cell, comprising a dihydroxy-acid dehydratase polypeptide. The invention is also related to a recombinant host cell having increased specific activity of the dihydroxy-acid dehydratase polypeptide as a result of increased expression of the polypeptide, modulation of the Fe—S cluster biosynthesis of the cell, or a combination thereof. The present invention also includes methods of using the host cells, as well as, methods for identifying polypeptides that increase the flux in an Fe—S cluster biosynthesis pathway in a host cell.Type: ApplicationFiled: November 1, 2016Publication date: April 13, 2017Inventors: Dennis Flint, Brian James Paul, Rick W. Ye
-
Publication number: 20170101654Abstract: The present invention relates to a method of enantioselective enzymatic transamination of (1R)-1-Hydroxy-1-Phenylacetone (R-PAC) to a chiral amine 1R, 2S-Norephedrine in the presence of an isopropylamine catalyzed by enantioselective transaminase. Isopropylamine is converted to acetone in the process. The transaminase used is in completely purified form, partially purified form or as whole cells. The source is microbial cells, which are genetically engineered. In the present invention, the enzyme is expressed in E. coli and used preferentially as a suspension of native cells. Transaminase comprising polypeptide sequence is obtained from Rhodobacter sphaeroides and expressed in E. coli. The nucleotide sequence of transaminase is expressed in an expression vector system pIEP/Kan/IEP AT12, which is incorporated in E. coli. The yield of 1R, 2S-1-norephedrine is greater than 87% and de % is greater than 99%.Type: ApplicationFiled: July 25, 2016Publication date: April 13, 2017Applicant: Embio LimitedInventors: Arumugam Govind SWAMINATHAN, Sunil Vaman JOSHI
-
Publication number: 20170101655Abstract: Disclosed is a microorganism of Escherichia sp. producing O-acetyl homoserine, and a method of producing O-acetyl homoserine in high yield using the microorganism.Type: ApplicationFiled: June 22, 2015Publication date: April 13, 2017Inventors: Hyun Ah KIM, Ju Hee SEO, Yong Uk SHIN, So Young KIM, Sang Kyoum KIM, Kwang Ho NA, Jee Yeon BAE, Sung Kwang SON, Hye Ryun YOO, Jin Geun CHOI
-
Publication number: 20170101656Abstract: Provided are a microorganism of the genus Escherichia for producing O-succinylhomoserine and a method for producing O-succinylhomoserine using the same.Type: ApplicationFiled: January 22, 2015Publication date: April 13, 2017Applicant: CJ CHEILJEDANG CORPORATIONInventors: Su Jin CHOI, Kuk Ki HONG, Young Lyeol YANG, Min Sun KANG, Hye Min PARK, Gyuhyeon SONG, Jong Hyun YOON
-
Publication number: 20170101657Abstract: The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.Type: ApplicationFiled: December 3, 2015Publication date: April 13, 2017Inventors: Vanessa RAGAGLIA, Vandana Madanlal SHARMA
-
Publication number: 20170101658Abstract: Disclosed herein are vector systems for expression of polypeptides in eukaryotic cells; and methods of obtaining high-level expression of polypeptides in a eukaryotic cell.Type: ApplicationFiled: July 20, 2015Publication date: April 13, 2017Applicant: Celltheon CorporationInventor: Amita Goel
-
Publication number: 20170101659Abstract: A method for increasing the molecular diversity of polyketides and non-ribsomomal peptides by using recombination to efficiently increase or decrease the number of modules in the polyketide synthase or non-ribosomal peptide synthetase encoding said polyketide or peptide.Type: ApplicationFiled: July 9, 2014Publication date: April 13, 2017Applicant: ISOMERASE THERAPEUTICS LTD.Inventors: Matthew Alan Gregory, Steven Gary Kendrew, Steven James Moss, Barrie Wikinson
-
Publication number: 20170101660Abstract: The present disclosure relates to an enzyme-immobilized porous membrane and a preparation method of antibiotics using the same, and more specifically, to an enzyme-immobilized porous membrane prepared by immobilizing a specific enzyme through dead-end filtration, and a preparation method of antibiotics with a high yield using the enzyme-immobilized porous membrane. According to various exemplary embodiments of the present disclosure, the enzyme capable of promoting the synthesis reaction of the antibiotic substance is able to be stably immobilized in the porous membrane by passing the solution of enzyme through the membrane. In addition, it is possible to provide antibiotics with a high yield by preparing the antibiotics by passing the reactant solution through the enzyme-immobilized porous membrane.Type: ApplicationFiled: October 7, 2016Publication date: April 13, 2017Inventors: Ji-woong Park, Sunoh Shin
-
Publication number: 20170101661Abstract: It is an object of the present invention to provide a sensor, which is capable of measuring, quickly and in high accuracy, concentration of neutral fat from a sample such as a biological sample or the like, without executing pretreatment of the sample. This object is attained by a biosensor for measuring concentration of neutral fat, based on value of current flowing in the electrode system, having: an insulating substrate; an electrode system having a working electrode and a counter electrode, formed onto the insulating substrate: and a reaction layer having a lipoprotein lipase, a glycerol dehydrogenase and an electron mediator, formed at the upper part or the vicinity of the electrode system.Type: ApplicationFiled: December 21, 2016Publication date: April 13, 2017Inventors: Hironobu Murase, Motoaki Kuwahara, Masayuki Yamada
-
Publication number: 20170101662Abstract: A detection system for determining pyruvate dehydrogenase (PDH) levels in a bodily sample includes at least one reaction solution for generating NAD+ upon combination with PDH in the bodily sample, the reaction solution including pyruvate and NADH and a biosensor for determining the level of generated NAD+.Type: ApplicationFiled: May 27, 2015Publication date: April 13, 2017Applicant: CASE WESTERN RESERVE UNIVERSITYInventor: Chung-Chiun Liu
-
Publication number: 20170101663Abstract: Methods are disclosed for distinguishing and identifying plants by measuring partial hydrolysis of polysaccharides on account of polysaccharide-hydrolyzing enzyme activity at pre-determined incubation times and temperatures. Methods also are disclosed for identifying the source organism of a heterologous polysaccharide-hydrolyzing enzyme in a plant by measuring partial hydrolysis of polysaccharides on account of polysaccharide-hydrolyzing enzyme activity at pre-determined incubation times and temperatures. The reaction mixture has unique chemical and physical properties that can be used to construct viscosity curves for measuring polysaccharide-hydrolyzing enzyme activity. The viscosity curves can be compared among plants to distinguish or identify the plants from one another. Likewise, viscosity curves can be compared among source organisms to identify the source organism of the heterologous polysaccharide-hydrolyzing enzyme in the plant.Type: ApplicationFiled: December 20, 2016Publication date: April 13, 2017Applicant: SYNGENTA PARTICIPATIONS AGInventors: Tricia C. Moser, Rene Quadt
-
Publication number: 20170101664Abstract: Disclosed are compositions and methods for measuring tyrosine kinase activity using degradation resistant biosensors comprising a reporter sequence, a target sequence, and a transduction sequence. In certain embodiments, the invention includes a biosensor comprising a peptide comprising a reporter sequence, i.e., an amino acid sequence including a tyrosine residue that can be phosphorylated by a tyrosine kinase. In certain embodiments, a biosensor comprises a reporter sequence configured to resist degradation from proteases, a targeting sequence coupled to the reporter sequence and configured to bind to a protein interaction domain of a kinase, and a transduction sequence coupled to the targeting sequence.Type: ApplicationFiled: April 29, 2015Publication date: April 13, 2017Applicant: Purdue Research FoundationInventors: Laurie L PARKER, Robert John SCHUSTER
-
Publication number: 20170101665Abstract: Compositions and methods of detecting multiple proteins of interest in a sample using arrays are provided herein.Type: ApplicationFiled: July 28, 2016Publication date: April 13, 2017Inventors: Sukanta BANERJEE, Michael SEUL, Hui HUANG